{"schema_version":"secwatch.filing_event.v1","accession":"0001739104-24-000004","form_type":"8-K","ticker":"ELAN","cik":"0001739104","company_name":"Elanco Animal Health Inc","filed_at":"2024-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.354589+00:00","generated_at":"2026-06-05T15:24:15.887076+00:00","sec_items":["2.02","2.05","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Elanco reports Q4 net loss $141M, full-year loss $1.23B; cuts 420 jobs in restructuring","bullets":["Q4 2023 revenue $1,035M (+5% YoY); reported net loss $141M ($0.29 EPS), adjusted EPS $0.08.","Full-year 2023 revenue $4,417M (flat YoY); net loss $1,231M; adjusted EBITDA $979M; adjusted EPS $0.89.","Full-year 2024 guidance: revenue $4,450-4,540M; adjusted EBITDA $960-1,010M; adjusted EPS $0.87-0.95.","Restructuring eliminates ~420 positions; charges $50-55M in 2024, annualized savings $30-35M.","Aqua business sale to Merck Animal Health for ~$1.3B expected mid-2024; proceeds to reduce debt."],"urls":{"canonical":"https://secwatch.observer/filing/0001739104-24-000004","json":"https://secwatch.observer/filing/0001739104-24-000004.json","markdown":"https://secwatch.observer/filing/0001739104-24-000004.md","text":"https://secwatch.observer/filing/0001739104-24-000004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1739104/000173910424000004/0001739104-24-000004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1739104/000173910424000004/elan-20240222.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T15:24:15.887076+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1387b19f98176198412031ce15f3943cc050d9bf","claim":"Elanco Animal Health Inc reported full year 2024 results: revenue Revenue of $4,450 to $4,540 million, net income Reported Net Loss of $17 to $62 million, EPS Reported EPS of $(0.12) to $(0.03). Guidance initiated.","evidence_excerpt":"Full Year 2024 Guidance: ◦ Revenue of $4,450 to $4,540 million ◦ Reported Net Loss of $17 to $62 million, Adjusted EBITDA of $960 to $1,010 million ◦ Reported EPS of $(0.12) to $(0.03), Adjusted EPS of $0.87 to $0.95","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1739104/000173910424000004/0001739104-24-000004-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year 2024"},{"label":"Revenue","value":"Revenue of $4,450 to $4,540 million"},{"label":"Net income","value":"Reported Net Loss of $17 to $62 million"},{"label":"EPS","value":"Reported EPS of $(0.12) to $(0.03)"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"7a5fe84670b25d27791a1e7406844ce07582bd35","claim":"Elanco Animal Health Inc reported the fiscal quarter ended December 31, 2023 results: revenue Revenue of $1,035 million, net income Reported Net Loss of $141 million, EPS Reported EPS of $(0.29).","evidence_excerpt":"Fourth Quarter 2023 Financial Results: ◦ Revenue of $1,035 million ◦ Reported Net Loss of $141 million, Adjusted Net Income of $39 million ◦ Adjusted EBITDA of $165 million or 15.9% of Revenue ◦ Reported EPS of $(0.29), Adjusted EPS of $0.08","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1739104/000173910424000004/0001739104-24-000004-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal quarter ended December 31, 2023"},{"label":"Revenue","value":"Revenue of $1,035 million"},{"label":"Net income","value":"Reported Net Loss of $141 million"},{"label":"EPS","value":"Reported EPS of $(0.29)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"7bc035e4aa9a4ddf97a3ffb50b10c0f5b8fbf8e6","claim":"Elanco Animal Health Inc reported the fiscal year ended December 31, 2023 results: revenue Revenue of $4,417 million, net income Reported Net Loss of $1,231 million, EPS Reported EPS of $(2.50).","evidence_excerpt":"Full Year 2023 Financial Results: ◦ Revenue of $4,417 million ◦ Reported Net Loss of $1,231 million, Adjusted Net Income of $439 million ◦ Adjusted EBITDA of $979 million or 22.2% of Revenue ◦ Reported EPS of $(2.50), Adjusted EPS of $0.89","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1739104/000173910424000004/0001739104-24-000004-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended December 31, 2023"},{"label":"Revenue","value":"Revenue of $4,417 million"},{"label":"Net income","value":"Reported Net Loss of $1,231 million"},{"label":"EPS","value":"Reported EPS of $(2.50)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"4fcb6f9465d2682523c05c24e9094fd31e0aea17","claim":"Elanco Animal Health Inc announced a restructuring with charges of $50 to $55 million affecting across our global organization (approximately 420 personnel).","evidence_excerpt":"On February 22, 2024, the Board of Directors of Elanco Animal Health Incorporated authorized a restructuring plan with respect to its workforce (the “Restructuring Plan”) to improve operational efficiencies and better align the Company’s organizational structure with current business needs, top strategic priorities and key growth opportunities. The restructuring plan will result in the elimination of approximately 420 personnel across our global organization. Expected pre-tax charges associated with the restructuring plan total $50 to $55 million in 2024, including $40 to $45 million of cash-based severance costs, a majority of which will be paid in 2024.","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1739104/000173910424000004/0001739104-24-000004-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"$50 to $55 million"},{"label":"Affected area","value":"across our global organization"},{"label":"Headcount","value":"approximately 420 personnel"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}